Search result6 min read

MDM2 vs MDM4: dependency and drugs side by side

MDM2 vs MDM4 in DepMap 24q4 Chronos data and drug annotations: 384 of 1178 cell lines depend on MDM2, 142 on MDM4; 12 drugs listed for MDM2, 1 for MDM4.

Data as of November 17, 2026 · By the BioQ team

BioQ result page for the query MDM2 showing the CRISPR dependency by lineage table and the list of known drugs.

In the depmap_24q4 Chronos data, MDM2 knockout meets the dependency criterion in 384 of 1178 cell lines (32.6%), while MDM4 does so in 142 of 1178 (12.1%). Neither gene is flagged as common essential. For drugs, 12 are listed for MDM2 and 1 for MDM4. The data are as of 2026-11-17.

What we asked: MDM2 vs MDM4 in one comparison

MDM2 and MDM4 are paralogs that both restrain p53, and researchers often ask whether they are interchangeable as targets. We put two questions to the same blocks for each gene:

  • How broadly and how strongly do cell lines depend on the gene in the CRISPR screen, and in which lineages?
  • Which drugs are annotated to the gene, at what clinical stage, and with what measured potency?

Running both genes through identical blocks keeps the comparison fair. Every difference below comes from the data, not from a different way of asking.

What BioQ returned

CRISPR dependency by lineage

The dependency blocks use the Chronos gene effect from DepMap. A more negative value means the knockout reduced viability more. A cell line counts as dependent when its effect falls at or below a named cutoff constant. That cutoff is a choice made in the analysis, not a property of the data. Both genes were scored across the same 1178 cell lines.

MDM2 first. The overall mean gene effect is -0.577, with 384 dependent lines (32.6%). The five lineages with the most negative mean effect:

LineageCell linesDependent% dependentMean gene effect
Eye1515100-1.504
Kidney342470.6-1.089
Pleura211466.7-1.04
Skin744763.5-1.038
Testis55100-0.891

Now MDM4, with the same layout:

LineageCell linesDependent% dependentMean gene effect
Eye15960-0.691
Peripheral Nervous System441534.1-0.429
Prostate10220-0.367
Pleura21628.6-0.337
Kidney34823.5-0.313

For MDM4 the overall mean gene effect is -0.183, with 142 dependent lines (12.1%).

Drugs known for each gene

For MDM2, 12 drugs are listed and 6 are shown here:

DrugMax clinical stageMechanismBest exact pChEMBLTypeTrials by name
NavtemadlinPHASE_3Tumour suppressor p53/oncoprotein Mdm2 inhibitor10.42KD9
IdasanutlinPHASE_3Tumour suppressor p53/oncoprotein Mdm2 inhibitor9.82KD14
SiremadlinPHASE_2Tumour suppressor p53/oncoprotein Mdm2 inhibitor9.68KI4
AlrizomadlinPHASE_2Tumour suppressor p53/oncoprotein Mdm2 inhibitor8.42IC501
QuisinostatPHASE_2———4
Cgm-097PHASE_1—9.1IC500
BioQ result for MDM2 with the drugs table listing navtemadlin, idasanutlin and siremadlin next to their clinical stage
The drugs block for MDM2 as BioQ returns it

For MDM4 the same query returns 1 drug, Sj-172550. Its maximum clinical stage is recorded as UNKNOWN. The record has no mechanism text, no exact pChEMBL value and 0 trials by name.

Behind these four blocks, BioQ ran 4 engine queries on 2 distinct resources, in 0.96 engine seconds in total. Doing this by hand means pulling a gene-level dependency table and a drug annotation list separately for each gene, then lining them up yourself.

What it means and how to read it

Where the genes differ. The MDM2 signal is broader and stronger by every measure in the facts. It has 384 dependent lines against 142, a mean effect of -0.577 against -0.183, and 32.6% against 12.1% dependent. In the drug layer, MDM2 has a populated list of 12 drugs, while MDM4 has one record with almost no annotation.

Where they are alike. Neither gene is common essential, so both dependencies are lineage-restricted rather than universal. Eye, Kidney and Pleura appear in the top five for both genes. Eye is the most sensitive lineage for each: all 15 eye lines depend on MDM2, and 9 of 15 (60.0%) depend on MDM4. Kidney has 24 of 34 dependent lines for MDM2 and 8 of 34 for MDM4. Pleura has 14 of 21 for MDM2 and 6 of 21 for MDM4. The ordering of lineages is partly shared even though the magnitudes are not.

Lineages that appear for only one gene. Skin (47 of 74) and Testis (5 of 5) are in the MDM2 top five. Peripheral Nervous System (15 of 44) and Prostate (2 of 10) are in the MDM4 top five. This only means they fall inside or outside the five rows shown for each gene. Prostate has only 10 lines, so its percentage rests on a small sample.

Drugs. The MDM2 list is led by Navtemadlin and Idasanutlin, both at PHASE_3, with exact pChEMBL values of 10.42 and 9.82. Siremadlin (9.68) and Alrizomadlin (8.42) are at PHASE_2. Quisinostat is also listed at PHASE_2 but has no mechanism text and no exact pChEMBL value, so it does not read like the other four. Cgm-097 is at PHASE_1 with 9.1 and no trials by name. A higher pChEMBL means a stronger measured potency, but the "Type" column (KD, KI, IC50) shows that these values come from different assay types and are not strictly interchangeable.

For selectivity questions, the useful reading is this: the dependency data show that the two genes are not equivalent in this screen, and the drug data show that the annotated pharmacology is concentrated on MDM2.

How to reproduce it in BioQ

  1. Open BioQ and enter the query below for the first gene.
MDM2

Open this query in BioQ

  1. Read the CRISPR dependency block: the scalars (dependent lines, percentage, mean gene effect) and the lineage table.
  2. Scroll to the drugs block and note the clinical stage, the exact pChEMBL value and the assay type for each drug.
  3. Repeat with MDM4 in place of MDM2, and compare the two sets of blocks row by row.
  4. Check the release label on each block, so you know which DepMap release and which drug sources the numbers come from.

Every answer names its source, so each number can be traced to the layer it came from.

Limits: what the data do not show

  • The lineage tables show only the top five lineages by mean gene effect for each gene. A lineage missing from one table is not necessarily absent from the other gene's wider data.
  • A dependency is defined by a named cutoff on the Chronos gene effect. A different cutoff would change the counts of dependent lines, though not the sign of the comparison in the mean effects.
  • The CRISPR screen measures viability in cell lines grown in culture. It says nothing about tumour response, p53 status of individual lines, or whether a lineage-level pattern holds in patients. The facts here do not break the dependency down by p53 status, so they cannot tell you whether the MDM2 and MDM4 patterns follow it.
  • "Trials by name" counts trials that mention the drug by name. It is not a curated list of trials against the target.
  • The single MDM4 record, Sj-172550, has no stage, mechanism or potency annotation here. The data cannot tell you how it compares with the MDM2 drugs.
  • Drug lists, stages and potencies are descriptive. Nothing here supports a statement about benefit, dosing or treatment.

Data and method

The numbers on this page were read from the BioQ engine on 2026-11-17 (4 queries, 1.0 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

/depmap, /drugs

Run the same query yourself: MDM2

For research use only. This page summarises public data and is not medical advice.

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

Queries used

Frequently asked questions

Is MDM2 or MDM4 a stronger CRISPR dependency in DepMap?

In depmap_24q4, MDM2 is the stronger dependency overall: 384 of 1178 cell lines (32.6%) are dependent, with a mean gene effect of -0.577. For MDM4 it is 142 lines (12.1%) and -0.183. Neither gene is common essential.

Which lineages depend most on MDM2 and MDM4?

Eye is the most sensitive lineage for both genes. All 15 eye lines depend on MDM2, and 9 of 15 (60.0%) depend on MDM4. Kidney and Pleura also appear in the top five for both.

How many drugs are known for MDM2 and for MDM4?

BioQ lists 12 drugs for MDM2 and 1 for MDM4. The MDM4 record, Sj-172550, has an UNKNOWN clinical stage and no exact pChEMBL value.

Which MDM2 inhibitors have reached the latest clinical stage in these data?

Navtemadlin and Idasanutlin are listed at PHASE_3, with exact pChEMBL values of 10.42 and 9.82. Siremadlin and Alrizomadlin are at PHASE_2, with 9.68 and 8.42.

How long did the MDM2 vs MDM4 comparison take in BioQ?

The four engine queries behind the comparison took 0.96 engine seconds in total and drew on 2 distinct resources.

Sources

  1. Dataset DepMap CRISPR Chronos gene effect (24Q4)
  2. Dataset Open Targets Platform; ChEMBL; Drug Repurposing Hub

Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.

More from the blog